Table 1 Schematic overview of study

From: Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy

Group

N

Week 0

Week 12

Week 24

Week 36

1

10

Ad26.Mos4.HIV

Ad26.Mos4.HIV

MVA-mosaic + placebo

MVA-mosaic + placebo

2

10a

Ad26.Mos4.HIV

Ad26.Mos4.HIV

Ad26.Mos4.HIV + clade C + mosaic gp140 (250 mcg + adjuvant)b

Ad26.Mos4.HIV + clade C + mosaic gp140 (250 mcg + adjuvant)b

3

6

Placebo

Placebo

Placebo + placebo

Placebo + placebo

  1. aPlanned enrolment number (study enrolled only 9 in this group).
  2. b250 mcg refers to total protein content (combination of Mosaic gp140 [125 mcg] and Clade C gp140 [125 mcg]). Sterile aluminum phosphate suspension was used as adjuvant. Aluminum content was 0.425 mg/0.5 mL dose.
Back to article page